ClotCare: Blood Clots, Stroke, Heart Attack
Thursday, September 21, 2017
Home   |   DVT/PE   |   Blood Clots   |   Coumadin/Warfarin   |   New Patients   |   Self Testing   |   Email List   |   Donate

Pick a Topic:

Find info on a:

We subscribe to the HONcode principles of the HON Foundation. Click to verify.
ClotCare complies with the HONcode standard for trustworthy health
information:
verify here.

ClotCare is a member of the Coalition to Prevent Deep Vein Thrombosis (DVT Coalition)  ClotCare is a member organization of the Coalition to Prevent Deep Vein Thrombosis. Click here to learn more about the Coalition to Prevent Deep Vein Thrombosis and DVT Awareness Month, which is held each March.

Overwhelmed by New Information on Pathogenesis (and Potential Treatments) of the Antiphospholipid Syndrome

Henry I. Bussey, Pharm.D.
April, 2013

The March 14, 2013 issue of the New England Journal of Medicine has a state of the art article with the deceptively simple title “The Pathogenesis of the Antiphospholipid Syndrome”.1

I suspect that many of us first encountered “the” antiphospholipid antibody syndrome (APAs) in the form of a patient with Lupus Anticoagulant (LAC). Most people who have LAC do not have “Lupus” (systemic lupus erythematosus or SLE), and they have a coagulation – not an anticoagulation – condition. This confusing terminology should have been an early clue to the complexity of this condition – or conditions. In addition, it was something of a mystery as to why some APAs patients seemed much more prone to clots than did others; some had problems with venous clotting while others had arterial clots; and still others had obstetrical problems. This article’s title held out the promise of defining “THE” pathogenesis of THE APAs but, in reality, the APAs is not one condition with a single pathogenesis. APAs – as clearly described in this article – is a complex mix of conditions and our understanding of the pathogenesis is getting more and more complex. This very thorough discussion is packed full of information on an evolving understanding of the many factors that contribute to the APAs; and it discusses multiple new and interesting potential avenues for treatment.

Some of the pathogenic factors discussed (beyond beta2 glycoprotein I antibodies) include the role of endothelial nitric oxide synthase, the A1 – A1 dimer of apolipoprotein E receptor 2, protein disulfide isomerase, the roles of factor XIa and XIIa, tissue factor, complement 5, complement 3, toll-like receptors 7 and 8 (TLR7, TLR8), reactive oxygen species, B cell activating factor (abbreviated BAFF), annexin A2 and annexin A5 (which appear to have opposing effects on clotting), and others. Potentially therapeutic agents discussed include N-acetylcysteine, hydroxychloroquine, the “statins”, inhibitors of factor XIa, belimumab (recently approved to treat SLE but also may reduce thrombosis), and eculizumab. Almost all of this information, and more, is combined into a single color diagram that may be an excellent teaching tool.

On a personal note, the complexity and depth of this paper clearly caused me to recognize the increasing value that I place on being able to call on the expertise of colleagues in hematology and immunology.

Reference

  1. Giannakopoulos B and Krilis SA. The Pathogenesis of the Antiphospholipid Syndrome. New England Journal of Medicine 2013; 368:1033-44. DOI: 10.1056/NEJMra1112830
Ask a question about blood clots or anticoagulant medications Have questions? Ask ClotCare. Send questions by email to webmaster@clotcare.org.

ClotCare is a 501(c)(3) non-profit organization generously supported by your tax-deductible donations and grants from our industry supporters.

Blood Clot Activities Calendar

New Postings:

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Rivaroxaban or Warfarin in Stable Coronary Artery Disease – Should the COMPASS Study Lead Us Back to the Future?

Click here to view full list of new postings
ClotCare Home | New Postings | Patient Postings | Clinician Postings | Join Our Email List | Useful Web Links
CE Opportunities | Training Programs | DVT & PE Stories | Editorial Board | Financial Support
About ClotCare | DVT Coalition | Donate to ClotCare | Contact Us
Key topics discussed on ClotCare include: Blood Clots | Deep Vein Thrombosis (DVT) | Pulmonary Embolism (PE) | Atrial Fibrillation (A. Fib or AF) | Heart Attack | Stroke | Transient Ischemic Attack (TIA) | Mini Stroke | Bleeding Complications | Vascular Surgery | Surgical Blood Clot Removal | Warfarin | Coumadin | Lovenox | Low Molecular Weight Heparin (LMWH) | Heparin | Anticoagulants | Plavix | Aspirin | Antiplatelets | Blood Thinners
Copyright 2000-2014 by ClotCare. All rights reserved.
Terms, Conditions, & Privacy | Image Copyright Information
19260 Stone Oak Parkway, Suite 101 | San Antonio, TX 78258 | 210-495-4335
Send comments to webmaster@clotcare.org.
Thursday, September 21, 2017